Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioAlliance Pharma Phase II follow up results showed a median survival of 32 months for Livatag (doxorubicin Transdrug) group, as compared with 15 months for cancer patients getting current best of care (TACE transarterial chemoembolisation with a cytotoxic drug).
Subscribe to our email newsletter
Livatag is a treatment presented in nanoparticles able to deliver doxorubicin in chemoresistant cells.
It was granted an orphan drug status in Europe and in the US.
The product is being evaluated in patients (via hepatic intra-arterial route) with advanced hepatocellular carcinoma.
BioAlliance Pharma CEO Dominique Costantini said Livatag is perfectly in line with their orphan product strategy and could be a significant value catalyst for the company.